Agios Pharma Files Routine 8-K for Regulatory Compliance

Ticker: AGIO · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1439222

Agios Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyAgios Pharmaceuticals, Inc. (AGIO)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, compliance, 8-K

TL;DR

**Agios Pharma filed a standard 8-K, signaling business as usual and regulatory compliance.**

AI Summary

Agios Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, indicating a routine filing for Regulation FD Disclosure and Financial Statements and Exhibits. This filing, under SEC File Number 001-36014, confirms the company's continued compliance with SEC reporting requirements. For investors, this matters because it signals that Agios is maintaining transparency and adhering to regulatory obligations, which is a foundational aspect of investor confidence and market integrity.

Why It Matters

This filing demonstrates Agios Pharmaceuticals' ongoing commitment to regulatory transparency, which is crucial for maintaining investor trust and market stability.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material information that would introduce significant risk.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate material news, and would continue to monitor for more substantive announcements like earnings or clinical trial results.

Key Numbers

  • 2024-01-08 — Filing Date (The date the 8-K was filed and the earliest event reported.)
  • 001-36014 — SEC File Number (Unique identifier for Agios Pharmaceuticals' filings with the SEC.)

Key Players & Entities

  • Agios Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • 001-36014 (string) — SEC File Number for Agios Pharmaceuticals
  • AGIO (string) — trading symbol for Agios Pharmaceuticals
  • Nasdaq Global Select Market (string) — exchange where Agios Pharmaceuticals' common stock is registered

FAQ

What is the purpose of this 8-K filing by Agios Pharmaceuticals, Inc.?

This 8-K filing by Agios Pharmaceuticals, Inc. is for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', as indicated in the 'ITEM INFORMATION' section of the filing.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 8, 2024, as stated in the 'Date of Report' section.

What is the trading symbol and the exchange where Agios Pharmaceuticals, Inc.'s common stock is registered?

Agios Pharmaceuticals, Inc.'s common stock trades under the symbol 'AGIO' and is registered on the 'Nasdaq Global Select Market', as detailed under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address of Agios Pharmaceuticals, Inc. as listed in the filing?

The business address of Agios Pharmaceuticals, Inc. is 88 Sidney Street, Cambridge, MA 02139, with a business phone number of (617) 649-8600, according to the 'BUSINESS ADDRESS' section.

Is Agios Pharmaceuticals, Inc. considered an emerging growth company according to this filing?

The filing includes a checkbox '☐ Indicate by check mark whether the registrant is an emerging growth company', which is not checked, implying that Agios Pharmaceuticals, Inc. does not identify as an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Filing Stats: 577 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-01-08 07:58:32

Key Financial Figures

  • $0.001 — ich registered Common Stock, Par Value $0.001 per share AGIO Nasdaq Global Select

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Agios Pharmaceuticals, Inc. (the "Company") issued a press release outlining its anticipated 2024 milestones and value-driving catalysts through 2026, which will be discussed at the Company's presentation at the 42 nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The slides to be presented by the Company at the 42 nd Annual J.P. Morgan Healthcare Conference are furnished as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued January 8, 2024. 99.2 Presentation at the 42 nd Annual J.P. Morgan Healthcare Conference 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGIOS PHARMACEUTICALS, INC. Date: January 8, 2024 By: /s/ Brian Goff Brian Goff Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.